CBPO - China Biologic Products Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.53
-0.47 (-0.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close82.00
Open82.66
Bid80.00 x 1000
Ask99.95 x 800
Day's Range81.45 - 82.66
52 Week Range71.85 - 107.44
Volume189,543
Avg. Volume352,330
Market Cap3.14B
Beta0.77
PE Ratio (TTM)39.50
EPS (TTM)2.06
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.24
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit12 hours ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $7 million over the last one-month.

  • Business Wire24 days ago

    David Gao Confirms Lawsuit Against China Biologic Products to Protect Shareholders’ Best Interests

    Mr. David (Xiaoying) Gao, a shareholder of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (CBPO), today confirmed that he filed a lawsuit against the Company related to its private placement of shares to a select investor group – including a private equity firm formed by Board Chairman David Li. It seeks to void and invalidate the agreements with Centurium Capital Management Ltd., CITIC Capital MB Investment Limited, Hillhouse Capital Management, Ltd. and PW Medtech.

  • PR Newswire25 days ago

    China Biologic Responds to Lawsuit Filed in Cayman Islands by Former Chairman

    "We deeply regret that Mr. David Gao, acting individually in his personal capacity, has attempted to challenge the completion of the private placement that was announced on August 24.  The Company is prepared to fend off meritless lawsuits like this and will take actions to seek actual and punitive damages from Mr. Gao in connection with his ill-intended lawsuit as well as any damages caused by breaches of his employment agreement. The Company continues to believe that the private placement transaction referred to in the lawsuit is beneficial to shareholders, through the additional capital and strategic partnerships which it will result in.

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CBPO totaled $1.57 billion.

  • Reuters29 days ago

    China Biologic rejects $3.9 bln bid from former CEO

    China Biologic Products Holdings Inc rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid. The consortium, which included China Biologic's former CEO David Gao, GL Capital Group, Bank of China Group Investment Ltd and CDH Investments, said on Monday it had offered $118 per share, $8 more than the CITIC unit's bid.

  • Business Wire29 days ago

    Leading Investor Group Issues Statement Following China Biologic’s Dilutive Private Placement of Shares

    A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today issued the following statement following China Biologic Products Holdings, Inc.’s (“China Biologic” or the “Company”) (CBPO) decision to conduct a dilutive private placement and reject the Consortium’s non-binding proposal to acquire all of the outstanding common shares of the Company for US$118.00 per share in cash. The Consortium’s proposal represented an approximate 30% premium to China Biologic’s closing share price on August 16, 2018, the last trading day before its proposal was conveyed. “We are deeply disappointed that China Biologic's Board has rejected our compelling proposal to deliver immediate and significant value to all shareholders.

  • The Wall Street Journal29 days ago

    [$$] China Biologic Says One Buyout Offer Is Withdrawn, Rejects Another

    China Biologic Products Holdings Inc. said Friday that one buyout proposal has been taken off the table--and it rejected another. Separately, China Biologic said it rejected a buyout offer from an investor group led by its former chairman and CEO David (Xiaoying) Gao. Mr. Gao’s proposal valued China Biologic at $3.9 billion as of Monday.

  • Here's Why China Biologic Products Stock Dropped Today
    Motley Fool29 days ago

    Here's Why China Biologic Products Stock Dropped Today

    After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.

  • Reuters29 days ago

    BRIEF-PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln

    Aug 24 (Reuters) - PW Medtech Group Ltd: * CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE * AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 ...

  • PR Newswire29 days ago

    China Biologic Announces Updates on Unsolicited Acquisition Proposals and Strategic Private Placement

    BEIJING, Aug. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's board of directors (the "Board") has received a letter dated August 23, 2018 from CITIC Capital MB Investment Limited, an affiliate of CITIC Capital Holdings Limited ("CITIC"), withdrawing its preliminary non-binding proposal dated June 11, 2018, with immediate effect. The Company further announced that the Board has unanimously decided to reject the previously announced preliminary non-binding proposal dated August 17, 2018 from the consortium (the "Consortium") consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited.

  • Reuterslast month

    Deals of the day-Mergers and acquisitions

    ** GlaxoSmithKline is seeking initial bids by mid-September for its India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said. ** Air Canada and its partners said that data analytics firm Aimia Inc had accepted a cash offer of C$450 million ($345 million) for the sale of its Aeroplan loyalty program. ** Mattress maker Serta Simmons Bedding LLC will merge with Tuft & Needle as the two companies look to take on stiff competition from cheaper Chinese products in the U.S. market.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Cronos and China Biologic Products

    NEW YORK, NY / ACCESSWIRE / August 21, 2018 / U.S. markets closed in the green on Monday as optimism over easing trade tensions and news of Pepsi Co.'s acquisition plans lifted indexes higher. The Dow ...

  • PR Newswirelast month

    China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal

    BEIJING, Aug. 21, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non-binding proposal letter from a consortium (the "Consortium") consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited to acquire all of the outstanding shares of the Company not already owned by the Consortium for US$118 per share in cash (the "Consortium Proposal"). A copy of the proposal letter from the Consortium is attached hereto as Annex A. The Company previously announced its receipt of the unsolicited, preliminary non-binding proposal letter from CCRE Holdings Limited to acquire all of the outstanding shares of the Company for US$110 per share in cash (the "CITIC Proposal").

  • Reuterslast month

    China Biologic gets $3.9 bln offer from former CEO-led consortium

    China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium of investment firms, valuing the Beijing-based company at slightly above an earlier buyout proposal ...

  • Here's Why China Biologic Products Stock Is Soaring Today
    Motley Foollast month

    Here's Why China Biologic Products Stock Is Soaring Today

    The blood plasma specialist has received a second buyout offer.

  • Reuterslast month

    China Biologic gets $3.9 billion offer from former CEO-led consortium

    (Reuters) - China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium of investment firms led by the company's former chief executive David Gao. The consortium, ...

  • MarketWatchlast month

    Consortium seeks to acquire China Biologic Products for $3.9 billion in cash

    A consortium composed of David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments is offering to buy China Biologic Products Holdings Inc. (cbpo) in an all-cash deal valued at about $3.9 billion. The consortium is offering $118 a share,equal to a roughly 30% premium over China Biologic's closing share price on Aug. 16, and a 40% premium over its close on June 8, the deay for CITIC Captial's make a $110 per share offer. Goldman Sachs is sole arranger, bookrunner and syndicated agent for a loan to finance the deal.

  • Business Wirelast month

    Leading Investor Group Proposes to Acquire China Biologic Products for US$118.00 Per Share in Cash

    A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today announced it has made a non-binding proposal to acquire all of the outstanding common shares of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (CBPO), that are not already held by the Consortium, for US$118.00 per share in an all-cash transaction valued at approximately US$3.9 billion. The proposal was conveyed on August 17, 2018 in a letter to China Biologic’s Board of Directors.

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $132 million over the last one-month.

  • PR Newswirelast month

    China Biologic Names Bing Li as New CEO

    BEIJING, Aug. 13, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's Board of Directors (the "Board") has appointed Dr. Bing Li as the Chief Executive Officer of the Company, effective August 13, 2018. Mr. Zhijun Tong, the former acting CEO, will continue to serve as an executive director of the Board and President of the Company.

  • Associated Press2 months ago

    China Biologic Products: 2Q Earnings Snapshot

    On a per-share basis, the Beijing-based company said it had profit of 83 cents. Earnings, adjusted for non-recurring costs, were $1.17 per share. The biopharmaceutical company posted revenue of $120.4 ...

  • PR Newswire2 months ago

    China Biologic Reports Financial Results for the Second Quarter of 2018

    -- 2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or   Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms ...

  • PR Newswire2 months ago

    China Biologic Products to Report Second Quarter 2018 Financial Results

    BEIJING , July 27, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • Ping An Said to Mull Rival Takeover Offer for China Biologic
    Bloomberg2 months ago

    Ping An Said to Mull Rival Takeover Offer for China Biologic

    Ping An Insurance (Group) Co., China’s largest insurer by market value, is considering a rival offer for plasma treatment provider China Biologic Products Holdings Inc., people familiar with the matter said. An arm of Ping An is in talks with other investors about a potential joint bid for Beijing-based China Biologic, according to the people, who asked not to be identified because the information is private. Any offer would be higher than the $110-per-share proposal from Chinese buyout firm Citic Capital, which valued U.S.-listed China Biologic at about $3.6 billion, the people said.

  • PR Newswire3 months ago

    China Biologic Announces Results of Its 2018 Annual General Meeting of Shareholders

    BEIJING, July 2, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the results of the Company's 2018 Annual General Meeting of Shareholders (the "Annual Meeting"), which was originally convened at 10:00 a.m. on Friday, June 29, 2018, and adjourned and re-convened at 10:00 a.m. on Monday, July 2, 2018. At the Annual Meeting, shareholders of the Company approved the re-election of each of Mr. Yungang Lu and Mr. Zhijun Tong as a Class III director to serve on the board of directors of the Company (the "Board") until the 2021 annual general meeting of shareholders, and ratified the appointment of KPMG Huazhen LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.